ÂÜÀòÂÒÂ×

Dr. Matthew Hemberger became the Senior Director of Chemistry, Manufacturing, and Controls (CMC) and Quality at ImmunoGenesis in February 2021. He joined the company after a long career at GlaxoSmithKline (GSK), most recently as the Director of Data Integrity for the joint venture between GSK and Pfizer. In that role, he led the global data integrity training programs, directed data analytics initiatives to improve issue detection, and provided subject matter expertise in the investigation of quality incidents globally.

In the Pharmaceutical Development group at GSK, Dr. Hemberger worked on multiple internal and external assets, including Horizant, which was granted NDA approval in April 2011, Cabenuva/Vocabria, and Blenrep. While at GSK, he also held roles in Global Manufacturing and Supply, where he assisted with the commercialization of assets, inspections, efficiency improvements, and regulatory responses. He has broad experience in a variety of dose forms, development strategies, large- and small-molecule assets, and auxiliary functions in the pharmaceutical industry.

He began his professional career at Mylan Pharmaceuticals as part of the Product Development group where his primary responsibilities included the development, validation, and transfer of analytical methods to support the company’s aggressive ANDA pipeline.

Dr. Hemberger holds a PhD in Analytical Chemistry from Florida State University and a BS in Chemistry from Viterbo University. His research at both institutions focused on chromatographic sciences.